GENE News Alert Genetic Technologies Ltd (GENE) 0.36 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genetic Technologies Ltd (GENE) 0.36 $GENE

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT
GlobeNewswire - Tue Dec 16, 10:23AM CST
Phenogen Sciences, Inc. (www.phenogensciences.com) announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms (SNPs) improves the predictive accuracy of four commonly-used breast cancer risk assessment models. This same panel of 77 SNPs is used in Phenogen Sciences' recently released BREVAGenplus(R), an easy-to-use predictive risk test for sporadic, or non-hereditary, breast cancer. Results were presented at the 2014 San Antonio Breast Cancer Symposium on December 13, 2014.
GENE: 0.36 (+0.01)

Genetic Technologies Announces Quarterly BREVAGen(TM) Results
Marketwire - Mon Oct 06, 4:42AM CDT
Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" reported 942 BREVAGen(TM) test samples received in the September Quarter 2014, ahead of the release of the second generation breast cancer risk assessment test, BREVAGenplus(R), in October 2014.
GENE: 0.36 (+0.01)

Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test
Marketwire - Wed Oct 01, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the Company's first generation product, BREVAGen(TM). BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
GENE: 0.36 (+0.01)

Genetic Technologies Announces Appointment of Independent Non-Executive Directors
Marketwire - Wed Sep 24, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have today been appointed Non-Executive Directors of the Company on "casual appointment", in that the new appointees will then be required to submit themselves for re-election at the upcoming AGM, as per article 19.4 of the Company's Constitution. The initial Director's interest notice - Appendix 3X, on behalf of Mr. Carter and Dr. Wakefield are attached.
GENE: 0.36 (+0.01)

Genetic Technologies Announces Divestment of Australian Based Heritage Business
Marketwire - Mon Sep 22, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce that it has signed a binding contract of sale for its heritage Australian Genetics business ("Australian Genetics" to Specialist Diagnostics Services Ltd ("SDS" , the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing. Under the terms of sale, SDS will acquire the Australian Genetics business for $2,000,000 in cash. Assuming all conditions are met, settlement of the transaction is expected to occur within the next month.
GENE: 0.36 (+0.01)

Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
Marketwire - Mon Sep 15, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to announce plans for the restructure and realignment of group activities. These changes will enable the Company to focus its strategy on the US molecular diagnostics ("MDx" market and commercialisation of the Company's lead breast cancer risk test BREVAGen(TM). The restructure and realignment of group activities follows a recent review of operations by the Company aimed at supporting the Company's US MDx strategy. The core plans approved by the Board include:
GENE: 0.36 (+0.01)

Genetic Technologies Announces Further Patent Success in USA
Marketwire - Tue Aug 26, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the United States District Court for the Middle District of North Carolina last week issued an Order denying a motion brought by GlaxoSmithKline, LLC (GSK) to dismiss the patent infringement law suit brought against it by GTG.
GENE: 0.36 (+0.01)

Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
GENE: 0.36 (+0.01)

Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
GENE: 0.36 (+0.01)

Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO" , dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013.
GENE: 0.36 (+0.01)

Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Marketwire - Wed Dec 18, 12:58PM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities" , have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%.
GENE: 0.36 (+0.01), AUQ: 3.08 (-0.12)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 31

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 5

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 44

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 70

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading

Top 5 Most Recently Viewed Articles

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome

Updated Category News Views 124

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome FINTEPLA, known scientifically as fenfluramine, has demonstrated remarkable potential in treating seizures associated with Lennox-Gastaut syndrome (LGS) as confirmed by a significant open-label extension (OLE) study. This study emphasized the drug's beneficial effects, particularly in lowering seizure...

Continue Reading
Implications of U.S. Withdrawal from the Paris Agreement

Updated Category News Views 370

Significance of the U.S. Withdrawal from the Paris Agreement The decision by the U.S. to withdraw from the Paris Agreement is a critical moment not just for America, but for the entire globe. Analysts and climate diplomats suggest that this move will have far-reaching consequences, more profound than those witnessed during the initial exit in recent years. Accelerating...

Continue Reading
Ambarella's Oculii AI Technology Enhances Lotus Electric Vehicles

Updated Category News Views 236

Ambarella's Oculii AI Radar Transforms Lotus Vehicles In a major technological breakthrough, Ambarella has announced the worldwide rollout of its Oculii™ AI 4D imaging radar technology in Lotus's 2023 and 2024 electric vehicles. This advanced technology is integrated into the eye-catching Lotus Eletre electric hyper-SUV and the thrilling Lotus Emeya hyper-GT models....

Continue Reading
Luxury Brands Adapt to Broader Market with Affordable Options

Updated Category News Views 355

Luxury Brands Embrace Affordability for Wider Appeal In recent times, luxury brands have found themselves in a challenging position. With diminishing demand for high-priced items like $3,000 handbags and $4,000 cashmere jackets, many luxury labels are shifting their focus. They are creating a wider array of products targeting the middle-class customer, including...

Continue Reading
Elife Group's Game-Changing Platform for Global Transport Solutions

Updated Category News Views 328

Elife Group Launches Revolutionary Multi-Modal Travel Platform Elife Group has introduced an innovative multi-modal platform that redefines ground transportation. By seamlessly integrating rail and ride-hailing services into a single platform, they have created a comprehensive solution for travelers seeking convenient and efficient options. This strategic move positions...

Continue Reading